Outcomes | Number of outcomes/Total number of patients | P-value | Odds Ratio (OR) (95%CI) | P-value $** | |
---|---|---|---|---|---|
Enoxaparin | UFH | ||||
All thrombosis cases, n(%)a | 3 (4.6) | 11 (18.3) | 0.02^^ | 4.10 (1.05,15.93) | 0.04 |
Major bleeding, n(%)a | 2 (3.1) | 2 (3.4) | 0.93** | 1.10 (0.14,8.56) | 0.93 |
All bleeding cases (major and minor), n(%)a | 5 (7.7) | 2 (3.1) | 0.24** | 0.40 (0.07,2.29) | 0.31 |
Requiring blood products transfusion during ICU stay, n(%)a | 4 (6.2) | 10 (16.9) | 0.06^^ | 2.98 (0.85,10.39) | 0.09 |
Heparin-associated thrombocytopenia (HAT), n(%)a | 11 (16.9) | 7 (10.8) | 0.31^^ | 0.48 (0.16,1.39) | 0.17 |
Heparin-induced thrombocytopenia (HIT), n(%)a | 1 (1.5) | 0 (0.0) | 0.32** | NC | NC |
 | Enoxaparin | UFH | P-value | Hazard Ratio (HR) (95%CI) | P-value $ |
30-day mortality, n (%)a | 20 (36.4) | 27 (57.4) | 0.03^^ | 0.90 (0.49, 1.64) | 0.73 |
In-hospital mortality, n (%)a | 21 (38.2) | 28 (56.0) | 0.07^^ | 1.18 (0.66, 2.13) | 0.57 |
 | Enoxaparin | UFH | P-value | beta coefficient (Estimates) (95%CI) | P-value $* |
Ventilator free days, Mean (SDa | 15.3 (13.59) | 11.8 (12.26) | 0.08^ | 0.08 (-0.67,0.83) | 0.83 |
ICU Length of Stay (Days), Median (Q1, Q3)a | 8.0 (5.00, 15.00) | 11.0 (6.00, 16.00) | 0.19^ | 0.05 (-0.19,0.29) | 0.66 |
Hospital Length of Stay (Days), Median (Q1, Q3)a | 13.0 (9.00, 19.00) | 19.0 (11.00, 25.00) | 0.01^ | 0.22 (-0.03,0.48) | 0.09 |